$CLMT

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

Original reporting
Published Aug 7, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Calumet Stock Flopped on Friday — source image
Decision brief

The 30-second read

$CLMTBearishMed
01

Why it matters

Traders likely focus on the earnings surprise and the stated drivers (RIN-related costs, hedging, and debt servicing), which can affect near-term sentiment and valuation for oil products refiners.

02

Market read

A reported net loss versus consensus profit is the immediate catalyst, with leverage and RIN/hedging effects framed as key contributors.

03

What to watch

The article flags long-term debt as a continuing headwind but does not quantify interest-rate sensitivity, covenant risk, or any refinancing timeline that could further change the risk premium.

Relevance 7/10Novelty 6/10Timing: post-earnings reaction on Friday

Background

The piece attributes Calumet’s Friday drop to a Q2 earnings report with a surprise net loss, despite higher revenue and improved adjusted EBITDA.

Company-level read

Ticker impact

$CLMTBearishMedium confidence
Context

Calumet shares fell nearly 6% after its Q2 earnings showed a surprise net loss versus analyst expectations of profit.

Expected impact

Near-term downside bias as traders reprice the earnings quality and debt-driven risk, despite stronger revenue and adjusted EBITDA.

Evidence & confidence

The article provides a concrete miss (net loss vs consensus EPS) and explains specific drivers, but it does not include guidance or balance-sheet changes beyond noting long-term debt.

Market effects

Highlights how renewable fuel credit (RIN) accounting, hedging, and financing costs can swing reported earnings for oil products refiners.

None specified.

None specified.

Counterpoint

Adjusted EBITDA and revenue rose meaningfully, suggesting the net loss may be more accounting and financing-driven than a collapse in operating performance.

Key entities

  • Calumet

    Oil products company whose Q2 earnings showed a surprise net loss and triggered a ~6% stock decline.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.